SCHEMBL312222

SCHEMBL312222

O=c1cc(-c2ccc(O)nc2O)oc2ccccc12

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 6/20 0.63
KDM4E B2RXH2 4/20 0.63
CYP3A4 P08684 4/20 0.63
MEN1 O00255 3/20 0.63
KMT2A Q03164 3/20 0.63
CYP2C9 P11712 2/20 0.63
CYP2C19 P33261 2/20 0.63
AKR1C3 P42330 1/20 0.62
AKR1C2 P52895 1/20 0.62
AKR1C1 Q04828 1/20 0.62
TP53 P04637 3/20 0.58
ALOX15 P16050 3/20 0.58
TDP1 Q9NUW8 2/20 0.58
MAPT P10636 2/20 0.58
HSD17B10 Q99714 2/20 0.58
CYP2D6 P10635 1/20 0.58
ALOX12 P18054 1/20 0.58
RECQL P46063 1/20 0.58
TNKS O95271 8/20 0.55
SMN1; SMN2 Q16637 5/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30933461 0.79 HPGD (0.75) HPGDKDM4ECYP3A4MEN1KMT2A
SCHEMBL9080220 0.78 AKR1C3 (0.72) HPGDKDM4ECYP3A4MEN1KMT2A
SCHEMBL4650047 0.78 HPGD (1.00) HPGDKDM4ECYP3A4MEN1KMT2A
SCHEMBL312255 0.77 AKR1C3 (1.00) HPGDKDM4ECYP3A4MEN1KMT2A
SCHEMBL1772778 0.77 HPGD (0.78) HPGDKDM4ECYP3A4MEN1KMT2A
SCHEMBL15676335 0.75 HPGD (0.74) HPGDKDM4ECYP3A4MEN1KMT2A
SCHEMBL21704894 0.75 HPGD (0.74) HPGDKDM4ECYP3A4MEN1KMT2A
SCHEMBL312401 0.75 KDM4E (0.59) HPGDKDM4ECYP3A4MEN1KMT2A
SCHEMBL311714 0.74 HPGD (0.76) HPGDKDM4ECYP3A4MEN1KMT2A
SCHEMBL311588 0.74 HPGD (0.76) HPGDKDM4ECYP3A4MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8242130-B2 Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases RESVERLOGIX CORP. (CA) 2012-08-14 US disclosed
EP-1838296-B1 FLAVANOIDS AND ISOFLAVANOIDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES RESVERLOGIX CORP (CA) 2012-08-08 EP disclosed
US-8093273-B2 Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases RESVERLOGIX CORP. (CA) 2012-01-10 US disclosed
EP-2332527-A2 Flavanoids and Isoflavanoids for the prevention and treatment of cardiovascular diseases RESVERLOGIX CORP. (CA) 2011-06-15 EP disclosed
US-20090259048-A1 FLAVANOIDS AND ISOFLAVANOIDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES RESVERLOGIX CORP. (CA) 2009-10-15 US disclosed
EP-1838296-A2 FLAVANOIDS AND ISOFLAVANOIDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES RESVERLOGIX CORP. (CA) 2007-10-03 EP disclosed
US-20060205767-A1 Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases HEPALINK (HONG KONG) LIMITED (HK) 2006-09-14 US disclosed
WO-2006045096-A2 FLAVANOIDS AND ISOFLAVANOIDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES RESVERLOGIX CORP. (CA) 2006-04-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060205767-A1 Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases APOB, APOL1, FABP3 HPGD 138/4885KDM4E 3504/4885CYP3A4 1730/4885
US-20090259048-A1 FLAVANOIDS AND ISOFLAVANOIDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES APOB, APOL1, FABP3 HPGD 138/4885KDM4E 3504/4885CYP3A4 1730/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.